home / stock / rttr / rttr news

RTTR News and Press, Ritter Pharmaceuticals From 07/11/19

Stock Information
Company Name: Ritter Pharmaceuticals
Stock Symbol: RTTR
Market: NASDAQ
Menu
RTTR RTTR Quote RTTR Short RTTR News RTTR Articles RTTR Message Board
Get RTTR Alerts

News, Short Squeeze, Breakout and More Instantly...
RTTR - Ritter Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that mo...
RTTR - Ritter up 6% premarket on advancement of RP-G28

Ritter Pharmaceuticals (NASDAQ: RTTR ) reports that the last participant in its Phase 3 Liberatus  study evaluating RP-G28 for the treatment of lactose intolerance has completed the final visit. More news on: Ritter Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,...

RTTR - Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 "Liberatus" Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the...

RTTR - Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an init...
RTTR - Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer

Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a dev...

RTTR - Ritter Pharmaceuticals beats by $0.12

Ritter Pharmaceuticals (NASDAQ: RTTR ): Q1 GAAP EPS of -$0.58 beats by $0.12 . More news on: Ritter Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RTTR - Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

LOS ANGELES, May 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initi...
RTTR - Ritter up 21% on advancement of lactose intolerance candidate RP-G28

Nano cap Ritter Pharmaceuticals ( RTTR +20.7% ) is up on more than a 6x surge in volume. Shares have rallied  40%  this week. More news on: Ritter Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

RTTR - Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut micr...

RTTR - Ritter Pharmaceuticals misses by $0.86

Ritter Pharmaceuticals (NASDAQ: RTTR ): FY GAAP EPS of -$3.66 misses by $0.86. More news on: Ritter Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Previous 10 Next 10